The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).
 
Nonna Shakhnazaryan
No Relationships to Disclose
 
Nathan Curry
No Relationships to Disclose
 
Medini Rastogi
No Relationships to Disclose
 
Daniel Avins
No Relationships to Disclose
 
Shrina Pandey
No Relationships to Disclose
 
Ivan de Kouchkovsky
Consulting or Advisory Role - Janssen
 
Daniel Kwon
No Relationships to Disclose
 
Arpita Desai
Consulting or Advisory Role - Aveo; Dendreon; Exelixis; Exelixis; Janssen; Janssen Oncology; Merck
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Merck
 
Kelly N. Fitzgerald
Consulting or Advisory Role - Janssen; MJH Life Sciences
 
Rohit Bose
Honoraria - Janssen; Qessential Medical Marketing Research; Tegus
 
Jonathan Chou
Consulting or Advisory Role - Exai Bio
Research Funding - Amgen (Inst)
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; EMD Serono
Consulting or Advisory Role - AADi; Astellas Pharma; Basilea; DAVA Oncology; EMD Serono; Foundation Medicine; Merck; Seagen; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Neon Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
 
Vadim S Koshkin
Consulting or Advisory Role - Clovis Oncology; Gerson Lehrman Group; Guidepoint Global; Janssen; MSD; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology (Inst); Endocyte (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Seagen (Inst); Taiho Oncology (Inst)
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma
Consulting or Advisory Role - Actym Therapeutics; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; EMD Serono; ImmunoGenesis; Innovent Biologics; Janssen Oncology; Merck; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Maya Aslam
No Relationships to Disclose
 
Khadija Siddiqua
No Relationships to Disclose
 
Eric J. Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Fortis; Janssen Oncology; Teon Therapeutics
 
Bin Liu
Leadership - Fortis
Stock and Other Ownership Interests - Fortis
Consulting or Advisory Role - Fortis
Patents, Royalties, Other Intellectual Property - Fortis
 
Robert R. Flavell
No Relationships to Disclose
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology